Get the Stockscreener App
0.9959
3.31%
-0.0341
Virax Biolabs Group Ltd Stock (VRAX) Forecast
The Virax Biolabs Group Ltd (VRAX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $4.9436, representing a +396.40% increase from the current price of $0.9959. The highest analyst price target is $5.0369, and the lowest is $4.8503.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month VRAX Price Target
Average 2.6059
(+161.66% Upside)
Is Virax Biolabs Group Ltd (VRAX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 27.44 | Buy |
| STOCH(9,6) | 14.85 | Buy |
| STOCHRSI(14) | 44.66 | Neutral |
| MACD(12,26) | -0.1471 | Sell |
| ADX(14) | 24.27 | Neutral |
| William %R | -91.74 | Buy |
| CCI(14) | -119.21 | Sell |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.1598
Sell
|
1.1313
Sell
|
| MA20 |
1.2417
Sell
|
1.2419
Sell
|
| MA50 |
1.547
Sell
|
1.4887
Sell
|
| MA100 |
1.7859
Sell
|
1.683
Sell
|
| MA200 |
1.9531
Sell
|
1.6416
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, VRAX could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 12 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on VRAX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 27.44 indicates that VRAX is oversold. This indicates that VRAX price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 14.85 indicates that VRAX is oversold. This indicates that VRAX price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 44.66 indicates that VRAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 24.27 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -119.21 indicates that VRAX is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term VRAX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Virax Biolabs Group Ltd financial reports and earnings history, Virax Biolabs Group Ltd (VRAX) stock could reach $6.0932 by 2030, $20.20 by 2040 and $38.87 by 2050. See the projected annual prices until 2050 of the Virax Biolabs Group Ltd stock below:
- Virax Biolabs Group Ltd (VRAX) is expected to reach an average price of $41.68 in 2035, with a high prediction of $43.42 and a low estimate of $41.71. This indicates an $4,086% rise from the last recorded price of $0.9959.
- Virax Biolabs Group Ltd (VRAX) stock is projected to chart a bullish course in 2040, with an average price target of $18.61, representing an $1,768% surge from its current level. The forecast ranges from a conservative $18.63 to a sky-high $20.20.
- Our analysts predict Virax Biolabs Group Ltd (VRAX) to jump 8,019% by 2045, soaring from $80.99 to an average price of $80.85, potentially reaching $83.93. While $80.99 is the low estimate, the potential upside is significant.
- Virax Biolabs Group Ltd (VRAX) stock is expected to climb by 2050, reaching an average of $34.18, a $3,332% jump from its current level. However, a wide range of estimates exists, with high and low targets of $38.87 and $34.22, respectively, highlighting the market's uncertainty.
Virax Biolabs Group Ltd Stock (VRAX) Year by Year Forecast
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2025
Virax Biolabs Group Ltd Stock (VRAX) is expected to reach an average price of $3.8776 in 2025, with a high prediction of $6.4165 and a low estimate of $1.3388. This indicates an +289.36% rise from the last recorded price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $4.8212 | $4.8503 | $5.0369 | +384.10% |
| June, 2025 | $4.4391 | $4.4694 | $4.6981 | +345.74% |
| July, 2025 | $4.0305 | $4.0316 | $4.3493 | +304.71% |
| August, 2025 | $3.6967 | $3.7197 | $3.9283 | +271.19% |
| September, 2025 | $3.4331 | $3.4529 | $3.5963 | +244.72% |
| October, 2025 | $2.954 | $2.9769 | $3.31 | +196.62% |
| November, 2025 | $2.6644 | $2.6933 | $2.8498 | +167.54% |
| December, 2025 | $1.3122 | $1.3388 | $1.2722 | +31.76% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2026
The predicted value for Virax Biolabs Group Ltd (VRAX) in 2026 is set at an average of $8.351. Estimates vary from a peak of $16.60 to a trough of $0.1027, indicating an +738.54% surge from the present price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.1492 | $1.2334 | $1.2656 | +15.40% |
| February, 2026 | $0.6246 | $0.6746 | $1.0382 | -37.28% |
| March, 2026 | $0.5389 | $0.5556 | $0.5103 | -45.89% |
| April, 2026 | $0.1649 | $0.1749 | $0.2668 | -83.44% |
| May, 2026 | $14.67 | $0.1027 | $12.12 | +1,373% |
| June, 2026 | $16.10 | $16.21 | $15.53 | +1,516% |
| July, 2026 | $16.93 | $16.26 | $16.40 | +1,600% |
| August, 2026 | $16.16 | $16.34 | $16.60 | +1,522% |
| September, 2026 | $15.50 | $15.57 | $15.91 | +1,457% |
| October, 2026 | $15.43 | $15.60 | $15.64 | +1,449% |
| November, 2026 | $14.64 | $14.72 | $14.97 | +1,370% |
| December, 2026 | $13.86 | $13.89 | $14.43 | +1,291% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Virax Biolabs Group Ltd (VRAX) is $8.7358, with a high forecast of $13.57 and a low forecast of $3.8988. This indicates an +777.18% increase from the last price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $13.06 | $13.10 | $13.57 | +1,211% |
| February, 2027 | $12.40 | $12.46 | $12.82 | +1,145% |
| March, 2027 | $11.69 | $11.75 | $12.15 | +1,074% |
| April, 2027 | $10.94 | $10.98 | $11.46 | +998.25% |
| May, 2027 | $10.25 | $10.25 | $10.63 | +929.01% |
| June, 2027 | $9.2906 | $9.3209 | $10.04 | +832.88% |
| July, 2027 | $8.6074 | $8.6134 | $9.1086 | +764.28% |
| August, 2027 | $7.8745 | $7.8877 | $8.411 | +690.70% |
| September, 2027 | $7.086 | $7.1059 | $7.6934 | +611.52% |
| October, 2027 | $6.3037 | $6.3533 | $6.8708 | +532.97% |
| November, 2027 | $5.6595 | $5.6608 | $6.1171 | +468.28% |
| December, 2027 | $3.8788 | $3.8988 | $5.4568 | +289.48% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2028
In 2028, Virax Biolabs Group Ltd (VRAX) is projected to reach an average price of $13.29, with a high projection of $25.78 and a low estimate of $0.8054. This indicates an +1,235% rise from the last price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $3.3712 | $3.4212 | $3.6344 | +238.51% |
| February, 2028 | $2.4712 | $2.5526 | $3.1279 | +148.14% |
| March, 2028 | $1.7947 | $1.8114 | $2.1593 | +80.21% |
| April, 2028 | $1.0842 | $1.1609 | $1.4305 | +8.86% |
| May, 2028 | $24.78 | $0.8054 | $22.23 | +2,388% |
| June, 2028 | $25.83 | $26.04 | $25.26 | +2,494% |
| July, 2028 | $25.97 | $25.72 | $25.46 | +2,507% |
| August, 2028 | $25.06 | $25.24 | $25.78 | +2,417% |
| September, 2028 | $24.05 | $24.36 | $24.73 | +2,315% |
| October, 2028 | $23.94 | $23.97 | $23.82 | +2,304% |
| November, 2028 | $22.35 | $22.43 | $23.48 | +2,144% |
| December, 2028 | $21.22 | $21.26 | $22.05 | +2,031% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2029
The 2029 price forecast for Virax Biolabs Group Ltd Stock (VRAX) is $13.71 on average, with a high prediction of $20.95 and a low estimate of $6.4698. This represents an +1,276% increase from the previous price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $19.94 | $19.98 | $20.95 | +1,902% |
| February, 2029 | $18.91 | $18.97 | $19.60 | +1,799% |
| March, 2029 | $18.07 | $18.08 | $18.48 | +1,715% |
| April, 2029 | $16.93 | $16.95 | $17.70 | +1,599% |
| May, 2029 | $15.56 | $15.57 | $16.62 | +1,462% |
| June, 2029 | $14.43 | $14.44 | $15.26 | +1,349% |
| July, 2029 | $13.35 | $13.37 | $14.12 | +1,240% |
| August, 2029 | $11.99 | $12.00 | $13.07 | +1,104% |
| September, 2029 | $10.96 | $10.98 | $11.72 | +1,001% |
| October, 2029 | $9.5879 | $9.6375 | $10.67 | +862.74% |
| November, 2029 | $8.5748 | $8.5761 | $9.3091 | +761.02% |
| December, 2029 | $6.3698 | $6.4698 | $8.28 | +539.60% |
Virax Biolabs Group Ltd Stock (VRAX) Price Forecast for 2030
Virax Biolabs Group Ltd Stock (VRAX) is expected to reach an average price of $18.31 in 2030, with a high forecast of $35.10 and a low forecast of $1.5081. This signifies an +1,738% surge from the last price of $0.9959.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $5.4569 | $5.5069 | $6.0932 | +447.93% |
| February, 2030 | $4.188 | $4.2694 | $5.1213 | +320.53% |
| March, 2030 | $3.2642 | $3.2733 | $3.7839 | +227.76% |
| April, 2030 | $2.2606 | $2.3245 | $2.9676 | +126.99% |
| May, 2030 | $33.92 | $1.5081 | $30.00 | +3,305% |
| June, 2030 | $35.36 | $34.93 | $35.04 | +3,451% |
| July, 2030 | $35.34 | $35.18 | $35.10 | +3,448% |
| August, 2030 | $34.49 | $34.55 | $34.97 | +3,363% |
| September, 2030 | $33.17 | $33.29 | $33.54 | +3,230% |
| October, 2030 | $32.11 | $32.14 | $32.54 | +3,124% |
| November, 2030 | $30.46 | $30.49 | $31.56 | +2,958% |
| December, 2030 | $28.82 | $28.96 | $29.96 | +2,794% |
2.65%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):